Increased sphingomyelinase activity in plasma was found in ALS patients with FUS, SOD1, and TBK1 mutations as well as transgenic mice expressing FUS-R521C; genetic inhibition of acid sphingomyelinase improved motor behavioral dysfunction in FUS-R521C mice [79]. This evidence concerns the gene FUS and amyotrophic lateral sclerosis.